Teresa Preglej

This study uses scRNA-seq and immunophenotyping to analyze immune changes in RA patients on MTX, showing early restoration of naive T/B cells and reduced memory T cells, with plasmablasts as a potential biomarker.

This study identifies primulagenin A as a potent inverse agonist of RORγ, showing efficacy in inhibiting Th17 cell differentiation and reducing IL-17A production.

This study screens histone acetylation inhibitors to modulate immune pathways in RA, showing concentration-dependent effects and overlap with existing RA drug pathways.

This paper shows that NorUDCA reduces TH17/Treg imbalance and intestinal inflammation by inhibiting glutaminolysis and mTORC1 signaling in TH17 cells.

This study shows that NorUDCA modulates CD8+ T cell metabolism and function, reducing hepatic inflammation in a mouse model of immune-mediated liver disease.